Genmab A/S (OTCMKTS:GNMSF) Short Interest Up 25.8% in April

Genmab A/S (OTCMKTS:GNMSF) was the recipient of a large increase in short interest in April. As of April 15th, there was short interest totaling 120,139 shares, an increase of 25.8% from the March 31st total of 95,479 shares. Based on an average trading volume of 81 shares, the short-interest ratio is currently 1,483.2 days. Currently, 0.2% of the company’s shares are sold short.

Genmab A/S Stock Performance

Shares of GNMSF stock remained flat at $255.25 during mid-day trading on Wednesday. The stock had a trading volume of 15 shares, compared to its average volume of 360. Genmab A/S has a 1 year low of $188.80 and a 1 year high of $352.00. The company has a market cap of $15.72 billion, a P/E ratio of 16.49 and a beta of 0.94. The stock’s 50 day simple moving average is $277.05 and its two-hundred day simple moving average is $302.45. The company has a current ratio of 2.02, a quick ratio of 2.01 and a debt-to-equity ratio of 0.86.

Genmab A/S (OTCMKTS:GNMSF) last issued its quarterly earnings data on Tuesday, February 17th. The company reported $0.55 EPS for the quarter, missing the consensus estimate of $3.10 by ($2.55). The company had revenue of $1.06 billion during the quarter, compared to analysts’ expectations of $1.05 billion. Genmab A/S had a return on equity of 17.35% and a net margin of 25.89%.

Genmab A/S Company Profile

Genmab A/S is a biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer and other serious diseases. The company’s core expertise lies in its proprietary antibody platforms, including DuoBody®, HexaBody® and HexElect®, which enable the design and engineering of novel bispecific and enhanced-effector antibodies. Genmab’s science-driven approach integrates advanced protein engineering with insights into tumor biology to generate candidates that can engage the immune system, disrupt disease pathways and offer potential safety and efficacy advantages over conventional therapies.

Founded in 1999 and headquartered in Copenhagen, Denmark, Genmab has grown into a global organization with research and development facilities in Utrecht, the Netherlands, and commercial and clinical support offices in the United States.